New Study Suggests Cancer Drug Could Be Used to Target Protein Connection That Spurs Parkinson’s Disease

In studies with genetically engineered mice, Johns Hopkins Medicine researchers say they have identified a potentially new biological target involving Aplp1, a cell surface protein that drives the spread of Parkinson’s disease-causing alpha-synuclein. The findings, published May 31, 2024 in Nature Communications, reveal how Aplp1 connects with Lag3, another cell surface receptor, in a key part of a process that helps spread harmful alpha-synuclein proteins to brain cells. Those protein buildups are hallmarks of Parkinson’s disease. The open-access article is titled “Aplp1 Interacts with Lag3 to Facilitate Transmission of Pathologic a-Synuclein.” Notably, the researchers say, Lag3 is already the target of a combination cancer drug approved by the U.S. Food and Drug Administration (FDA) that uses antibodies to “teach” the human immune system what to seek and destroy.
Login Or Register To Read Full Story